N
EVMN

Natixis’s Evommune Inc EVMN Stock Holding History

Natixis’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.4K Buy
+5,044
New +$117K ﹤0.01% 1011

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Natixis's EVMN Position: Q2 2026 in Review

Natixis opened a new position in Evommune Inc (EVMN) in Q2 2026: 5,044 shares worth $69.4K. The stake represents ﹤0.01% of the portfolio and ranks #1011 among its holdings.

105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Natixis held 5,044 shares of Evommune Inc worth $69.4K as of Q2 2026.
  • Evommune Inc was a new Natixis position in Q2 2026.
  • Evommune Inc made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1011 holding.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.